Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors
Sanborn, Rachel E, Pishvaian, Michael J, Callahan, Margaret K, Weise, Amy, Sikic, Branimir I, Rahma, Osama, Cho, Daniel C, Rizvi, Naiyer A, Sznol, Mario, Lutzky, Jose, Bauman, Julie E, Bitting, Rhonda L, Starodub, Alexander, Jimeno, Antonio, Reardon, David A, Kaley, Thomas, Iwamoto, Fabio, Baehring, Joachim M, Subramaniam, Deepa S, Aragon-Ching, Jeanny B, Hawthorne, Thomas R, Rawls, Tracey, Yellin, Michael, Keler, Tibor
Published in Journal for immunotherapy of cancer (01.08.2022)
Published in Journal for immunotherapy of cancer (01.08.2022)
Get full text
Journal Article
406 CDX527–01, a phase 1 dose-escalation and expansion study of the PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies
Yellin, Michael, Rawls, Tracey, Young, Diane, Golden, Philip, Vitale, Laura, He, Li-Zhen, Thomas, Lawrence, Keler, Tibor
Published in Journal for immunotherapy of cancer (01.11.2020)
Published in Journal for immunotherapy of cancer (01.11.2020)
Get full text
Journal Article
A phase 1 dose-escalation study of a PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies
Sanborn, Rachel E., Bordoni, Rodolfo Eduardo, Fleming, Gini F., Khasraw, Mustafa, Hawthorne, Thomas, Thomas, Lawrence J, Rawls, Tracey, Young, Diane C., Golden, Philip, Keler, Tibor, Yellin, Michael Jay
Published in Journal of clinical oncology (20.05.2021)
Published in Journal of clinical oncology (20.05.2021)
Get full text
Journal Article
ATIM-23. ANTI-CD27 AGONIST ANTIBODY VARLILUMAB IN COMBINATION WITH NIVOLUMAB FOR RECURRENT GLIOBLASTOMA (rGBM): PHASE 2 CLINICAL TRIAL RESULTS
Reardon, David, Kaley, Thomas, Iwamoto, Fabio, Baehring, Joachim, Subramaniam, Deepa, Rawls, Tracey, He, Yi, Keler, Tibor, Yellin, Michael
Published in Neuro-oncology (Charlottesville, Va.) (05.11.2018)
Published in Neuro-oncology (Charlottesville, Va.) (05.11.2018)
Get full text
Journal Article
Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies
Ansell, Stephen M., Flinn, Ian, Taylor, Matthew H., Sikic, Branimir I., Brody, Joshua, Nemunaitis, John, Feldman, Andrew, Hawthorne, Thomas R., Rawls, Tracey, Keler, Tibor, Yellin, Michael J.
Published in Blood advances (12.05.2020)
Published in Blood advances (12.05.2020)
Get full text
Journal Article
Abstract LB-194: First-in-human Phase I study of the CD40 agonist mAb CDX-1140 and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers: Interim results
Sanborn, Rachel E., Gabrail, Nashat Y., Bhardwaj, Nina, Gordon, Michael S., O'Hara, Mark, Khalil, Danny, Hawthorne, Thomas, Gedrich, Richard, Vitale, Laura, Rogalski, Mark, Li, Tianshu, Rawls, Tracey, Keler, Tibor, Yellin, Michael
Published in Cancer research (Chicago, Ill.) (01.07.2019)
Published in Cancer research (Chicago, Ill.) (01.07.2019)
Get full text
Journal Article
Clinical results with combination of anti-CD27 agonist antibody, varlilumab, with anti-PD1 antibody nivolumab in advanced cancer patients
Sanborn, Rachel E., Pishvaian, Michael J., Kluger, Harriet M., Callahan, Margaret K., Weise, Amy M., Lutzky, Jose, Yellin, Michael Jay, Rawls, Tracey, Vitale, Laura, Halim, Abdel, Keler, Tibor, Davis, Tom, Rizvi, Naiyer A.
Published in Journal of clinical oncology (20.05.2017)
Published in Journal of clinical oncology (20.05.2017)
Get full text
Journal Article
Anti-CD27 agonist antibody varlilumab (varli) with nivolumab (nivo) for colorectal (CRC) and ovarian (OVA) cancer: Phase (Ph) 1/2 clinical trial results
Sanborn, Rachel E., Pishvaian, Michael J., Callahan, Margaret K., Weise, Amy M., Sikic, Branimir I., Rahma, Osama E., Cho, Daniel C., Rizvi, Naiyer A., Bitting, Rhonda L., Starodub, Alexander, Jimeno, Antonio, Yellin, Michael Jay, Rawls, Tracey, Vitale, Laura, Halim, Abdel, Zhang, Hui, Keler, Tibor
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article
Abstract CT023: Phase I results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward immune-related adverse events
Sanborn, Rachel E., Pishvain, Michael J., Callahan, Margaret K., Rizvi, Naiyer, Kluger, Harriet, Yellin, Michael, Rawls, Tracey, Vitale, Laura, Halim, Abdel, Davis, Tom, Keler, Tibor
Published in Cancer research (Chicago, Ill.) (15.07.2016)
Published in Cancer research (Chicago, Ill.) (15.07.2016)
Get full text
Journal Article